Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | TNKS | O95271 | 2/20 | 0.30 |
| ▸ | PARP1 | P09874 | 2/20 | 0.30 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16865825 | 0.70 | SCN10A (0.31) | — | |
| SCHEMBL21393119 | 0.68 | CAPN1 (0.49) | — | |
| SCHEMBL13869104 | 0.67 | HPGD (0.37) | HPGDKDM4EALDH1A1LMNAMAPT | |
| SCHEMBL13101094 | 0.63 | HPGD (0.46) | HPGDALDH1A1 | |
| SCHEMBL22907603 | 0.63 | HPGD (0.41) | HPGDKDM4EALDH1A1 | |
| SCHEMBL889062 | 0.61 | — | — | |
| SCHEMBL21324833 | 0.61 | HPGD (0.32) | HPGD | |
| SCHEMBL13869105 | 0.61 | DHFR (0.30) | — | |
| SCHEMBL13920210 | 0.60 | ALDH1A1 (0.37) | HPGDKDM4EALDH1A1LMNAMAPT | |
| SCHEMBL12621290 | 0.58 | HPGD (0.33) | HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240209017-A1 | STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-06-27 | — | — | US | disclosed |
| US-20240209017-A1 | STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-06-27 | — | — | US | disclosed |
| US-11542293-B2 | Sting modulator compounds, and methods of making and using | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-01-03 | — | — | US | disclosed |
| US-20210171565-A1 | STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-06-10 | — | — | US | disclosed |
| US-20210015915-A1 | STING MODULATOR COMPOUNDS WITH SULFAMATE LINKAGES, AND METHODS OF MAKING AND USING | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11542293-B2 | Sting modulator compounds, and methods of making and using | STING1, CGAS, MAVS | HPGD 1860/4885KDM4E 2160/4885ALDH1A1 4763/4885 |
| US-20210015915-A1 | STING MODULATOR COMPOUNDS WITH SULFAMATE LINKAGES, AND METHODS OF MAKING AND USING | STING1, CGAS, TBK1 | HPGD 1489/4885KDM4E 2154/4885ALDH1A1 4387/4885 |
| US-20240209017-A1 | STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING | STING1, CGAS, MAVS | HPGD 1860/4885KDM4E 2160/4885ALDH1A1 4763/4885 |
| US-20210171565-A1 | STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING | STING1, CGAS, MAVS | HPGD 1860/4885KDM4E 2160/4885ALDH1A1 4763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.